Roxanne Lagano Sells 923 Shares of Zoetis Inc. (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Roxanne Lagano also recently made the following trade(s):

• On Monday, March 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59.
• On Monday, February 12th, Roxanne Lagano sold 363 shares of Zoetis stock. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62.

Zoetis Trading Down 4.3 %

Shares of Zoetis stock opened at $146.45 on Friday. The firm has a 50-day moving average of $175.48 and a 200-day moving average of $180.02. The stock has a market cap of $66.98 billion, a PE ratio of 28.89, a PEG ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a 52-week low of $145.80 and a 52-week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.15 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.18%. Zoetis’s payout ratio is presently 34.12%.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently modified their holdings of the business. Kesler Norman & Wride LLC lifted its position in Zoetis by 4.7% during the first quarter. Kesler Norman & Wride LLC now owns 6,316 shares of the company’s stock worth $1,069,000 after purchasing an additional 284 shares during the period. Retirement Guys Formula LLC bought a new stake in Zoetis during the first quarter worth about $554,000. Oak Harvest Investment Services lifted its position in Zoetis by 73.2% during the first quarter. Oak Harvest Investment Services now owns 8,959 shares of the company’s stock worth $1,516,000 after purchasing an additional 3,787 shares during the period. AMI Asset Management Corp lifted its position in Zoetis by 2.5% during the first quarter. AMI Asset Management Corp now owns 364,833 shares of the company’s stock worth $61,733,000 after purchasing an additional 8,790 shares during the period. Finally, Legacy Wealth Asset Management LLC lifted its position in Zoetis by 1.7% during the first quarter. Legacy Wealth Asset Management LLC now owns 8,307 shares of the company’s stock worth $1,406,000 after purchasing an additional 137 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ZTS. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. The Goldman Sachs Group lifted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Barclays lifted their price objective on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.